je.st
news
Tag: approves
NEPCO Approves 10Mvar STATCOM by Jema for Operation in Jordan
2016-10-25 22:52:00| Transmission & Distribution World
Jordanian national electricity company NEPCO has accepted the STATCOM 10Mvar supplied by Jema to ensure compliance with the grid code of a 24-MW photovoltaic (PV) plant. After exhaustive factory tests at full power, the STATCOM has undergone successful site tests at the PV plant in Ma’an, which included integration tests with the central plant control, full power operation of the STATCOM and behavior during LVRT. read more
Tags: in
operation
jordan
approves
Italy approves 3 Italia/Wind tie-up
2016-10-25 02:00:00| Total Telecom industry news
But report claims government's budget plan could jeopardise the merger altogether.
US Federal Maritime Commission approves OCEAN Alliance
2016-10-25 01:00:00| Ship Technology
The US Federal Maritime Commission (FMC) has approved the formation of OCEAN Alliance, a joint collaboration between COSCO Shipping, CMA CGM, Evergreen Marine, and Orient Overseas Container Line (OOCL).
Tags: federal
commission
ocean
alliance
UK Government approves third runway at Heathrow Airport
2016-10-25 01:00:00| Airport Technology
The UK Government has approved the construction of a third runway at Heathrow Airport.
Tags: government
airport
approves
runway
FDA Approves Mercks KEYTRUDA (pembrolizumab) in Metastatic NSCLC for First-Line Treatment of Patients Whose Tumors Have High PD-L1 Expression (Tumor Proportion Score [TPS] of 50 Percent or More) With No EGFR or ALK Genomic Tumor Aberrations
2016-10-25 00:04:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is the Only Anti-PD-1 Therapy Approved in First-Line Treatment of Metastatic NSCLC; KEYTRUDA Demonstrated Superior Progression-Free and Overall Survival Compared to Chemotherapy in Patients Whose Tumors Expressed High Levels of PD-L1 FDA Also Approves a Labeling Update for KEYTRUDA for the Treatment of Patients with Metastatic NSCLC Whose Tumors Express PD-L1 (TPS of One Percent or More) With Disease Progression On or After Platinum-Containing Chemotherapy; Patients With EGFR or ALK Genomic Tumor Aberrations Should Have Disease Progression On FDA-Approved Therapy for These Aberrations Prior to Receiving KEYTRUDA KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have high PD-L1 expression (tumor proportion score [TPS] of 50 percent or more) as determined by an FDA-approved test, with no EGFR or ALK genomic tumor aberrations. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558Courtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986Amy Klug, 908-740-1898 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Sites : [88] [89] [90] [91] [92] [93] [94] [95] [96] [97] [98] [99] [100] [101] [102] [103] [104] [105] [106] [107] next »